Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
Blood Advances
|
March 27, 2026
Exercise in MPNs: a promising first step
Joan How
Current Hematologic Malignancy Reports
|
September 3, 2021
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera
Joan How, Gabriela Hobbs
Cancers
|
July 26, 2020
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How, Gabriela Hobbs
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera
Joan How, Gabriela Hobbs
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
Pregnancy: MPN management before, during, and after pregnancy
Joan How, Gabriela Hobbs
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic
Joan How, Gabriela S Hobbs
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Blast and accelerated phase CML: room for improvement
Joan How, Vinayak Venkataraman, Gabriela Soriano Hobbs
Postgraduate Medicine
|
January 22, 2021
Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants
Joan How, Charlotte Story, Jean Marie Connors
Blood
|
September 29, 2019
Mutant calreticulin in myeloproliferative neoplasms
Joan How, Gabriela S Hobbs, Ann Mullally
Blood
|
December 19, 2022
Biology and therapeutic targeting of molecular mechanisms in MPNs
Joan How, Jacqueline S Garcia, Ann Mullally
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
Blood Advances
|
March 27, 2026
Exercise in MPNs: a promising first step
Joan How
Current Hematologic Malignancy Reports
|
September 3, 2021
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera
Joan How, Gabriela Hobbs
Cancers
|
July 26, 2020
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How, Gabriela Hobbs
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera
Joan How, Gabriela Hobbs
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
Pregnancy: MPN management before, during, and after pregnancy
Joan How, Gabriela Hobbs
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic
Joan How, Gabriela S Hobbs
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Blast and accelerated phase CML: room for improvement
Joan How, Vinayak Venkataraman, Gabriela Soriano Hobbs
Postgraduate Medicine
|
January 22, 2021
Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants
Joan How, Charlotte Story, Jean Marie Connors
Blood
|
September 29, 2019
Mutant calreticulin in myeloproliferative neoplasms
Joan How, Gabriela S Hobbs, Ann Mullally
Blood
|
December 19, 2022
Biology and therapeutic targeting of molecular mechanisms in MPNs
Joan How, Jacqueline S Garcia, Ann Mullally
Page
of 5